91189-18-3

Basic information

• Product Name: tert-Butyl 1-benzhydryl-3-azetidinylcarbamate
• Synonyms: tert-Butyl 1-benzhydryl-3-azetidinylcarbamate;[1-(Diphenylmethyl)-3-azetidinyl]-carbamic acid 1,1-dimethylethyl ester;tert-butyl 1-benzhydrylazetidin -3-ylcarbamate;tert-butyl 2-aMino-1-(diphenylMethyl)azetidine-3-carboxylate;tert-butyl 1-benzhydrylazrtidin-3-ylcarbaMate
• CAS NO: 91189-18-3
• Molecular Formula: C₂₁H₂₆N₂O₂
• Molecular Weight: 338.44
• Product Categories: Azetidines
• Mol File: 91189-18-3.mol

Chemical Properties

• Boiling Point: 448.8 °C at 760 mmHg
• Flash Point: 225.2 °C
• Appearance: /
• Density: 1.13 g/cm³
• Vapor Pressure: 3.02E-08mmHg at 25°C
• Refractive Index: 1.59
• Storage Temp.: 2-8°C
• CAS DataBase Reference: tert-Butyl 1-benzhydryl-3-azetidinylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 1-benzhydryl-3-azetidinylcarbamate(91189-18-3)
• EPA Substance Registry System: tert-Butyl 1-benzhydryl-3-azetidinylcarbamate(91189-18-3)

Safety Data

• Hazardous Substances Data: 91189-18-3(Hazardous Substances Data)

Usage

Chemical Properties

White powder

InChI:InChI=1/C21H26N2O2/c1-21(2,3)25-20(24)22-18-14-23(15-18)19(16-10-6-4-7-11-16)17-12-8-5-9-13-17/h4-13,18-19H,14-15H2,1-3H3,(H,22,24)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 40432-52-8 1-benzhydrylazetidin-3-ylamine 
• 33301-41-6 1-benzhydryl-3-azetidinyl methanesulfonate 
• 18621-17-5 1-(diphenylmethyl)-3-hydroxyazetidine 

Downstream Products

• 40432-52-8 1-benzhydrylazetidin-3-ylamine 
• 91188-13-5 tert-butyl 3-azetidinylcarbamate 
• 854038-91-8 N-(1-benzhydrylazetidin-3-yl)-N-methylcarbamic acid tert-butyl ester 
• 217806-26-3 tert-butyl N-(azetidin-3-yl)carbamate hydrochloride 
• 929716-70-1 tert-butyl (1-benzhydrylazetidin-3-yl)(ethyl)carbamate 

Relevant articles and documents

Efficient Manufacturing Process for the Selective Estrogen Receptor Degrader GDC-9545 (Giredestrant) via a Crystallization-Driven Diastereoselective Pictet-Spengler Condensation

GDC-9545 is a selective estrogen receptor degrader that is being developed as a treatment for ER+/HER2- breast cancer. A robust, convergent manufacturing process for GDC-9545 was developed. The process features a Wenker aziridine synthesis to produce the key starting material tryptamine 11, a highly efficient C-N coupling between aminoazetidine 9 and 2,6-difluoro-4-bromobenzaldehyde diethyl acetal (33) to construct key intermediate 10, and a crystallization-driven diastereoselective Pictet-Spengler reaction to furnish the active pharmaceutical ingredient GDC-9545·tartrate.

4-(3-Aminoazetidin-1-yl)pyrimidin-2-amines as High-Affinity Non-imidazole Histamine H3 Receptor Agonists with in Vivo Central Nervous System Activity

Despite the high diversity of histamine H3 receptor (H3R) antagonist/inverse agonist structures, partial or full H3R agonists have typically been imidazole derivatives. An in-house screening campaign intriguingly afforded

2-AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR ACTIVITY

2-Aminopyrimidine derivatives of formula (I), wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as modulators of the H4 receptor.

GUANIDINO-SUBSTITUTED QUINAZOLINONE COMPOUNDS AS MC4-R AGONISTS

A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the structure IA, IB, and IC where the values of the variables are defined herein.

Alpha 1a adrenergic receptor antagonists

This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.